EHA 2022 | Orca-T, a promising platform to treat GvHD
Everett Meyer
• 6 Jun 2022
Everett Meyer, MD, PhD, Stanford University, Stanford, CA, gives an overview of the Orca-T platform and comments on its impact in reducing both acute and chronic graft-versus-host disease (GvHD) without impacting relapse. Dr Meyer also shares his excitement about the possibility of integrating Orca-T with allogeneic CAR-Ts. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Dr Meyer receives research funding at Stanford University to support the conduct of the clinical trials discussed from Orca Biosystems.
